戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s associated with 2'-C-cyano-2',3'-didehydro-2',3'-dideoxycytidine.
2 ed sensitivity to the mitochondrial toxicant 2'-3'-dideoxycytidine.
3 been approved for human use: azidothymidine; 2'3'-dideoxycytidine; 2'3'-dideoxyinosine; 2', 3'-didehy
4 aturated series, L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine 24 and 5-fluorocytidine 26 showed
5 S-octadecyl-2-O-palmitoyl-1-thioglycerol (2) 2',3'-dideoxycytidine 5'-diphosphate-rac-1-S-octadecyl-2
6 methoxyphenyl ether, the target 4'-C-ethynyl-2',3'-dideoxycytidine analogue (rac-1h) was obtained aft
7 presence of reverse transcriptase inhibitors 2',3'-dideoxycytidine and a tetrahydroimidazo[4,5,1-jk](
8 esia caused by HIV/AIDS antiretroviral [ddC (2',3'-dideoxycytidine)] and anticancer (oxaliplatin) che
9           In contrast, 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and 3'-azidothymidine, which are
10  the anti-human immunodeficiency virus agent 2',3'-dideoxycytidine (approximately 6-fold) and the ant
11 mately 20% of normal levels by treating with 2',3'-dideoxycytidine (ddC) and subsequently allowed rec
12                                              2',3'-dideoxycytidine (ddC) is a synthetic pyrimidine nu
13  are modified cytosine analogs, Zalcitabine (2',3'-dideoxycytidine (ddC)) and Lamivudine (beta-d-(+)-
14 ',3'-didehydro-2',3'-dideoxythymidine (D4T), 2',3'-dideoxycytidine (ddC), (-)-beta-L-2',3'-dideoxy-3'
15 ells to the mtDNA depletion caused by beta-d-2',3'-dideoxycytidine (ddC), 2',3'-didehydro-2',3'-dideo
16  include D-nucleoside analogs such as beta-D-2',3'-dideoxycytidine (ddC), beta-2'-fluoro-5-methyl-ara
17 te to cellular tolerance to CTNAs, including 2',3'-dideoxycytidine (ddC), cytarabine (ara-C) and zido
18        The first-generation NRTIs, including 2',3'-dideoxycytidine (ddC), were originally and are sti
19 ditionally exhibited low-level resistance to 2',3'-dideoxycytidine (ddC).
20 athway activity, we used a nucleoside analog 2'3'-dideoxycytidine (ddC), which is phosphorylated to t
21 dideoxy-5-fluorocytidine (beta-L-FddCTP) and 2', 3'-dideoxycytidine (ddCTP), on DNA strand elongation
22  reducing resistance to tenofovir, abacavir, 2',3'-dideoxycytidine, dideoxyinosine, and stavudine.
23 eta-l-2',3'-dideoxy-3'-thiocytidine > beta-d-2',3'-dideoxycytidine > beta-d-2',2'-difluorodeoxycytidi
24 y-2', 3'-didehydro-5-fluorocytidine > beta-l-2',3'-dideoxycytidine > beta-l-2',3'-dideoxy-3'-thiocyti
25 lls and an 82-fold increase in the IC(50) to 2',3'-dideoxycytidine in Jurkat cells.
26  exhibited antinociception in a zalcitabine (2'-3'-dideoxycytidine) model of AIDS therapy-induced and
27                The L-enantiomers of 5-fluoro-2',3'-dideoxycytidine monophosphate and triphosphate had
28 side reverse transcriptase inhibitor (NRTI), 2',3'-dideoxycytidine or 2',3'-dideoxyinosine, mtDNA dep
29 '-azidothymidine therapy in combination with 2',3'-dideoxycytidine or 2',3'-dideoxyinosine.
30 sphorylated to the activated antimetabolite, 2'3'-dideoxycytidine triphosphate by cytoplasmic nucleos
31 mbination therapy with zidovudine (AZT) plus 2',3'-dideoxycytidine was found to regain sensitivity to
32 uoro-2',3'-dideoxy-3'-thiacytidine) and ddC (2',3'-dideoxycytidine) were added to the cultures beginn